{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:44:53Z","timestamp":1792100693956,"version":"4.4.0"},"reference-count":241,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1124\/pr.59.2.2","type":"journal-article","created":{"date-parts":[[2007,5,31]],"date-time":"2007-05-31T19:33:20Z","timestamp":1180640000000},"page":"151-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Pharmacological Treatment of the Overweight Patient"],"prefix":"10.1016","volume":"59","author":[{"given":"George A.","family":"Bray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L.","family":"Greenway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pr.59.2.2_REF1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/oby.2002.86","article-title":"Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial","volume":"10","author":"Anderson","year":"2002","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1046\/j.1365-2826.2003.01043.x","article-title":"Activation of the hypothalamic arcuate nucleus predicts the anorectic actions of ciliary neurotrophic factor and leptin in intact and gold thioglucose-lesioned mice","volume":"15","author":"Anderson","year":"2003","journal-title":"J Neuroendocrinol"},{"key":"10.1124\/pr.59.2.2_REF3","first-page":"64","article-title":"Dexfenfluramine for obesity","volume":"38","author":"Anonymous","year":"1996","journal-title":"Med Lett Drugs Ther"},{"key":"10.1124\/pr.59.2.2_REF4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","article-title":"Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine","volume":"106","author":"Apfelbaum","year":"1999","journal-title":"Am J Med"},{"key":"10.1124\/pr.59.2.2_REF5","first-page":"R749","article-title":"Mice lacking melanin-concentrating hormone receptor 1 demonstrate increased heart rate associated with altered autonomic activity","volume":"287","author":"Astrand","year":"2004","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.59.2.2_REF6","first-page":"269","article-title":"The effect and safety of an ephedrine\/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double blind trial","volume":"16","author":"Astrup","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF7","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/oby.2004.206","article-title":"Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects","volume":"12","author":"Astrup","year":"2004","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF8","doi-asserted-by":"crossref","unstructured":"Astrup A, Greenway FL, Ling W, Pedicone L, Lachowicz J, Strader CD, and Kwan R (2007) Randomized controlled trials of the D1\/D5 antagonist ecopipam for weight loss in obese subjects. Obes Res, in press.","DOI":"10.1038\/oby.2007.205"},{"issue":"Suppl","key":"10.1124\/pr.59.2.2_REF9","first-page":"167S","article-title":"Topiramate: a new potential pharmacological treatment for obesity","volume":"12","author":"Astrup","year":"2004","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-277X.2004.00530.x","article-title":"What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behavior therapy or combinations of these interventions","volume":"17","author":"Avenell","year":"2004","journal-title":"J Hum Nutr Diet"},{"key":"10.1124\/pr.59.2.2_REF11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1620\/tjem.202.173","article-title":"Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?","volume":"202","author":"Aydin","year":"2004","journal-title":"Tohoku J Exp Med"},{"key":"10.1124\/pr.59.2.2_REF12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.ijo.0802298","article-title":"Short-term effects of sibutramine (Reductil) on appetite and eating behavior and the long-term therapeutic outcome","volume":"27","author":"Barkeling","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF13","doi-asserted-by":"crossref","first-page":"245S","DOI":"10.1093\/jn\/133.1.245S","article-title":"Increased dairy product or calcium intake: is body weight or composition affected in humans?","volume":"133","author":"Barr","year":"2003","journal-title":"J Nutr"},{"key":"10.1124\/pr.59.2.2_REF14","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJMoa030204","article-title":"Inhibition of food intake in obese subjects by peptide YY3\u201336","volume":"349","author":"Batterham","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.59.2.2_REF15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1517\/13543784.11.9.1189","article-title":"Anti-obesity drug development","volume":"11","author":"Bays","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/pr.59.2.2_REF16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/sj.ejcn.1602121","article-title":"Bioactive food stimulants of sympathetic activity: effect on 24-h energy expenditure and fat oxidation","volume":"59","author":"Belza","year":"2005","journal-title":"Eur J Clin Nutr"},{"key":"10.1124\/pr.59.2.2_REF17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/oby.2003.78","article-title":"Predictors of weight loss in adults with topiramate-treated epilepsy","volume":"11","author":"Ben-Menachem","year":"2003","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF18","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/mol.63.4.908","article-title":"The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa\/fa rats and in cultured adipocyte cells","volume":"63","author":"Bensaid","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.59.2.2_REF19","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.amjcard.2004.07.137","article-title":"Safety and efficacy of citrus aurantium for weight loss","volume":"94","author":"Bent","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1124\/pr.59.2.2_REF20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-145-2-200607180-00005","article-title":"Weight loss in adolescents treated with sibutramine: a randomized, placebo-controlled trial","volume":"145","author":"Berkowitz","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.59.2.2_REF21","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1001\/jama.289.14.1805","article-title":"Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial","volume":"289","author":"Berkowitz","year":"2003","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pr.59.2.2_REF22","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1463-1326.2006.00602.x","article-title":"Interim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes","volume":"8","author":"Blonde","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pr.59.2.2_REF23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s002130050178","article-title":"Sumatriptan decreases food intake and increases plasma growth hormone in healthy women","volume":"129","author":"Boeles","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1124\/pr.59.2.2_REF24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.ijo.0801539","article-title":"An herbal supplement containing ma huang-guarana for weight loss: a randomized, double-blind trial","volume":"25","author":"Boozer","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/jm00235a030","article-title":"Catechol O-methyltransferase. 5. Structure-activity relationships for inhibition by flavonoids","volume":"18","author":"Borchardt","year":"1975","journal-title":"J Med Chem"},{"key":"10.1124\/pr.59.2.2_REF26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nm741","article-title":"Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist","volume":"8","author":"Borowsky","year":"2002","journal-title":"Nat Med"},{"key":"10.1124\/pr.59.2.2_REF27","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/01.RES.0000132745.76882.70","article-title":"Angiogenesis inhibitor TNP-470, prevents diet-induced and genetic obesity in mice","volume":"94","author":"Brakenhielm","year":"2004","journal-title":"Circ Res"},{"issue":"Suppl","key":"10.1124\/pr.59.2.2_REF28","first-page":"A28","article-title":"Intranasal peptide YY 3\u201336: phase 1 dose ranging and dose sequencing studies","volume":"12","author":"Brandt","year":"2004","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.ijo.0802479","article-title":"Obesity is a chronic, relapsing neurochemical disease","volume":"28","author":"Bray","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss","volume":"7","author":"Bray","year":"1999","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00005792-197507000-00002","article-title":"Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature","volume":"54","author":"Bray","year":"1975","journal-title":"Medicine (Baltimore)"},{"key":"10.1124\/pr.59.2.2_REF32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1210\/edrv.20.6.0383","article-title":"Current and potential drugs for treatment of obesity","volume":"20","author":"Bray","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1124\/pr.59.2.2_REF33","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity","volume":"11","author":"Bray","year":"2003","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1742-1241.2002.tb11307.x","article-title":"Randomized trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study","volume":"56","author":"Broom","year":"2002","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pr.59.2.2_REF35","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF36","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/ajcn\/56.5.863","article-title":"Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan","volume":"56","author":"Cangiano","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/pr.59.2.2_REF37","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/sj.ijo.0800642","article-title":"Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in noninsulin dependent diabetic patients","volume":"22","author":"Cangiano","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF38","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jn\/132.6.1107","article-title":"Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats","volume":"132","author":"Cefalu","year":"2002","journal-title":"J Nutr"},{"key":"10.1124\/pr.59.2.2_REF39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jsgi.2005.10.006","article-title":"Effects of Chinese green tea on weight, and hormonal and biochemical profiles in obese patients with polycystic ovary syndrome\u2014a randomized placebo-controlled trial","volume":"13","author":"Chan","year":"2006","journal-title":"J Soc Gynecol Investig"},{"key":"10.1124\/pr.59.2.2_REF40","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","article-title":"Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial","volume":"293","author":"Chanoine","year":"2005","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pr.59.2.2_REF41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1078\/0944-7113-00078","article-title":"Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity","volume":"9","author":"Chantre","year":"2002","journal-title":"Phytomedicine"},{"key":"10.1124\/pr.59.2.2_REF42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diacare.19.6.667","article-title":"Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects","volume":"19","author":"Cincotta","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF43","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-143-5-200509060-00013","article-title":"Anorectics on trial: a half century of federal regulation of prescription appetite suppressants","volume":"143","author":"Colman","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.59.2.2_REF44","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2337\/diacare.27.5.1077","article-title":"Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients","volume":"27","author":"Damci","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial","volume":"281","author":"Davidson","year":"1999","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pr.59.2.2_REF46","first-page":"4635","article-title":"Calcium intake and body weight","volume":"85","author":"Davies","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pr.59.2.2_REF47","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2174\/1381612013397339","article-title":"\u03b23-Adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans","volume":"7","author":"de Souza","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1124\/pr.59.2.2_REF48","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF49","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1053\/j.gastro.2005.09.001","article-title":"Effect of peptide YY3\u201336 on food intake in humans","volume":"129","author":"Degen","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1124\/pr.59.2.2_REF50","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.59.2.2_REF51","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/WNL.54.4.973","article-title":"Stable weight during lamotrigine therapy: a review of 32 studies","volume":"54","author":"Devinsky","year":"2000","journal-title":"Neurology"},{"key":"10.1124\/pr.59.2.2_REF52","first-page":"299","article-title":"The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks","volume":"19","author":"Drent","year":"1995","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF53","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/ajcn\/70.6.1040","article-title":"Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans","volume":"70","author":"Dulloo","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/pr.59.2.2_REF54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sj.ijo.0801101","article-title":"Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity","volume":"24","author":"Dulloo","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"Suppl","key":"10.1124\/pr.59.2.2_REF55","first-page":"S135","article-title":"Increased fecal fat excretion in normal volunteers treated with lipase inhibitor ATL-962","volume":"26","author":"Dunk","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"Suppl 1","key":"10.1124\/pr.59.2.2_REF56","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.jada.2005.02.028","article-title":"Dietary supplements in weight reduction","volume":"105","author":"Dwyer","year":"2005","journal-title":"J Am Diet Assoc"},{"key":"10.1124\/pr.59.2.2_REF57","first-page":"E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.59.2.2_REF58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cmet.2006.08.002","article-title":"Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults","volume":"4","author":"Erondu","year":"2006","journal-title":"Cell Metab"},{"key":"10.1124\/pr.59.2.2_REF59","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1001\/jama.289.14.1826","article-title":"Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study","volume":"289","author":"Ettinger","year":"2003","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pr.59.2.2_REF60","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1172\/JCI0215693","article-title":"Beneficial effects of leptin on obesity T cell hyporesponsiveness, and neuroendocrine\/metabolic dysfunction of human congenital leptin deficiency","volume":"110","author":"Farooqi","year":"2002","journal-title":"J Clin Investig"},{"key":"10.1124\/pr.59.2.2_REF61","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/dmrr.499","article-title":"Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes","volume":"20","author":"Fineman","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1124\/pr.59.2.2_REF62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1463-1326.2000.00071.x","article-title":"Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"2","author":"Finer","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pr.59.2.2_REF63","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0031-9384(95)02098-5","article-title":"Effect of fenfluramine on food intake, mood, and performance of humans living in a residential laboratory","volume":"59","author":"Foltin","year":"1996","journal-title":"Physiol Behav"},{"key":"10.1124\/pr.59.2.2_REF64","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/diacare.19.9.920","article-title":"The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution: BIGPRO Study Group","volume":"19","author":"Fontbonne","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF65","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/gut.52.11.1555","article-title":"Effect of a somatostatin analog on gastric motor and sensory functions in healthy humans","volume":"52","author":"Foxx-Orenstein","year":"2003","journal-title":"Gut"},{"key":"10.1124\/pr.59.2.2_REF66","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1210\/jc.2004-1657","article-title":"Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial","volume":"90","author":"Franco","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pr.59.2.2_REF67","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1463-1326.2000.00081.x","article-title":"Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus","volume":"2","author":"Fujioka","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pr.59.2.2_REF68","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1001\/jama.289.14.1820","article-title":"Zonisamide for weight loss in obese adults: a randomized controlled trial","volume":"289","author":"Gadde","year":"2003","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pr.59.2.2_REF69","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/oby.2001.71","article-title":"Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women","volume":"9","author":"Gadde","year":"2001","journal-title":"Obes Res"},{"issue":"Suppl","key":"10.1124\/pr.59.2.2_REF70","first-page":"A17","article-title":"A 24-week randomized controlled trial of VI-0521, a combination weight loss therapy, in obese adults","volume":"14","author":"Gadde","year":"2006","journal-title":"Obesity"},{"key":"10.1124\/pr.59.2.2_REF71","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.ijo.0803223","article-title":"Atomoxetine for weight reduction in obese women: a preliminary randomized controlled trial","volume":"30","author":"Gadde","year":"2006","journal-title":"Int J Obes (Lond)"},{"key":"10.1124\/pr.59.2.2_REF72","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/en.2004-1349","article-title":"Exenatide (exendin-4) improves insulin sensitivity and \u03b2-cell mass in insulin-resistant obese fa\/fa Zucker rats independent of glycemia and body weight","volume":"146","author":"Gedulin","year":"2005","journal-title":"Endocrinology"},{"key":"10.1124\/pr.59.2.2_REF73","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1139\/y04-025","article-title":"Mutational analysis of the serotonin receptor 5HT2c in severe early-onset human obesity","volume":"82","author":"Gibson","year":"2004","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1124\/pr.59.2.2_REF74","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/jc.2004-0263","article-title":"Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study","volume":"90","author":"Godoy-Matos","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pr.59.2.2_REF75","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.ijo.0802436","article-title":"Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal","volume":"27","author":"Goedecke","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF76","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1463-1326.2002.00181.x","article-title":"Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity","volume":"4","author":"Gokcel","year":"2002","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 4","key":"10.1124\/pr.59.2.2_REF77","first-page":"481S","article-title":"Efficacy and safety of long-term fluoxetine treatment of obesity\u2013maximizing success","volume":"3","author":"Goldstein","year":"1995","journal-title":"Obes Res"},{"issue":"Suppl","key":"10.1124\/pr.59.2.2_REF78","doi-asserted-by":"crossref","first-page":"203S","DOI":"10.1093\/ajcn\/55.1.203s","article-title":"Clinical studies with phenylpropanolamine: a meta-analysis","volume":"55","author":"Greenway","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/pr.59.2.2_REF79","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1467-789x.2001.00038.x","article-title":"The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent","volume":"2","author":"Greenway","year":"2001","journal-title":"Obes Rev"},{"issue":"Suppl 1","key":"10.1124\/pr.59.2.2_REF80","first-page":"A394","article-title":"Bupropion and naltrexone for the treatment of obesity","volume":"55","author":"Greenway","year":"2006","journal-title":"Diabetes Metab"},{"issue":"Suppl","key":"10.1124\/pr.59.2.2_REF81","first-page":"A17","article-title":"Bupropion and zonisamide for the treatment of obesity","volume":"14","author":"Greenway","year":"2006","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF82","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1089\/jmf.2006.9.572","article-title":"Dietary herbal supplements with phenylephrine for weight loss","volume":"9","author":"Greenway","year":"2006","journal-title":"J Med Food"},{"key":"10.1124\/pr.59.2.2_REF83","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1001\/archsurg.137.10.1109","article-title":"Effects of obesity surgery on noninsulin-dependent diabetes mellitus","volume":"137","author":"Greenway","year":"2002","journal-title":"Arch Surg"},{"key":"10.1124\/pr.59.2.2_REF84","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.ijo.0803283","article-title":"Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial","volume":"30","author":"Hackman","year":"2006","journal-title":"Int J Obes (Lond)"},{"key":"10.1124\/pr.59.2.2_REF85","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.ijo.0801889","article-title":"Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials","volume":"26","author":"Haddock","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF86","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.7624777","article-title":"Weight-reducing effects of the plasma protein encoded by the obese gene","volume":"269","author":"Halaas","year":"1995","journal-title":"Science (Wash DC)"},{"key":"10.1124\/pr.59.2.2_REF87","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1021\/jm058239j","article-title":"Melanin-concentrating hormone-1 receptor antagonists","volume":"49","author":"Handlon","year":"2006","journal-title":"J Med Chem"},{"key":"10.1124\/pr.59.2.2_REF88","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/ajcn\/68.6.1180","article-title":"Thermogenic effects of sibutramine in humans","volume":"68","author":"Hansen","year":"1998","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/pr.59.2.2_REF89","first-page":"S100","article-title":"Weight reduction by sibutramine in obese subjects in primary care medicine: the S.A.T. study (Abstract)","volume":"24","author":"Hauner","year":"2000","journal-title":"Int J Obes Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF90","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/ENDO:13:2:201","article-title":"Orlistat: selective inhibition of caloric absorption can affect long-term body weight","volume":"13","author":"Hauptman","year":"2000","journal-title":"Endocrine"},{"key":"10.1124\/pr.59.2.2_REF91","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.59.2.2_REF92","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/jama.280.18.1596","article-title":"Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial","volume":"280","author":"Heymsfield","year":"1998","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pr.59.2.2_REF93","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","article-title":"Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial","volume":"282","author":"Heymsfield","year":"1999","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pr.59.2.2_REF94","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.160.9.1321","article-title":"Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults","volume":"160","author":"Heymsfield","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1124\/pr.59.2.2_REF95","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/ajcn\/69.6.1108","article-title":"Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study","volume":"69","author":"Hill","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/pr.59.2.2_REF96","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1210\/jc.2003-030346","article-title":"Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Hoffman","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pr.59.2.2_REF97","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF98","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1753-4887.2001.tb07001.x","article-title":"Dietary fiber and weight regulation","volume":"59","author":"Howarth","year":"2001","journal-title":"Nutr Rev"},{"key":"10.1124\/pr.59.2.2_REF99","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/ajcn\/77.4.771","article-title":"Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men","volume":"77","author":"Hukshorn","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/pr.59.2.2_REF100","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/sj.bjp.0701312","article-title":"Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat","volume":"121","author":"Jackson","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.59.2.2_REF101","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/oby.2002.142","article-title":"Bupropion SR versus placebo for weight loss in obese patients with depressive symptoms","volume":"10","author":"Jain","year":"2002","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF102","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"key":"10.1124\/pr.59.2.2_REF103","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.ijo.0802887","article-title":"Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials","volume":"29","author":"Jordan","year":"2005","journal-title":"Int J Obes (Lond)"},{"key":"10.1124\/pr.59.2.2_REF104","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ceca.2005.10.005","article-title":"Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic \u03b2-cell","volume":"39","author":"Juan-Pico","year":"2006","journal-title":"Cell Calcium"},{"key":"10.1124\/pr.59.2.2_REF105","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2337\/diacare.20.11.1697","article-title":"Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women","volume":"20","author":"Kamath","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF106","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0026-895X(24)12241-9","article-title":"A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist J-115814","volume":"59","author":"Kanatani","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.59.2.2_REF107","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","article-title":"Entry of exendin-4 into brain is rapid but may be limited at high doses","volume":"27","author":"Kastin","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF108","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.biopha.2004.09.006","article-title":"Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients","volume":"58","author":"Kaya","year":"2004","journal-title":"Biomed Pharmacother"},{"key":"10.1124\/pr.59.2.2_REF109","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulintreated type 2 diabetes: a 1-year randomized controlled trial","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF110","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF111","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1056\/NEJM200012213432501","article-title":"Phenylpropanolamine and the risk of hemorrhagic stroke","volume":"343","author":"Kernan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.59.2.2_REF112","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/oby.2003.152","article-title":"Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials","volume":"11","author":"Kim","year":"2003","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF113","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00008877-200509000-00004","article-title":"Endocannabinoids in the regulation of appetite and body weight","volume":"16","author":"Kirkham","year":"2005","journal-title":"Behav Pharmacol"},{"key":"10.1124\/pr.59.2.2_REF114","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1124\/pr.59.2.2_REF115","first-page":"A395","article-title":"A randomized, placebo-controlled, trial of cetilistat (ATL-962), a novel lipase inhibitor and orlistat (Xenical) for the management of obese type 2 diabetic patients","volume":"55","author":"Kopelman","year":"2006","journal-title":"Diabetes Metab"},{"key":"10.1124\/pr.59.2.2_REF116","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1079\/BJN20041061","article-title":"Effects of green tea on weight maintenance after body-weight loss","volume":"91","author":"Kovacs","year":"2004","journal-title":"Br J Nutr"},{"key":"10.1124\/pr.59.2.2_REF117","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejphar.2004.06.027","article-title":"Melanin-concentrating hormone-1 receptor antagonism decreases feeding by reducing meal size","volume":"497","author":"Kowalski","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.59.2.2_REF118","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pr.59.2.2_REF119","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.ijo.0801568","article-title":"Physical activity and dietary fiber determine population body fat levels: the Seven Countries Study","volume":"25","author":"Kromhout","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF120","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/jc.2004-1719","article-title":"Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men","volume":"90","author":"Laferrere","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pr.59.2.2_REF121","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1194\/jlr.R300011-JLR200","article-title":"Efficacy and safety of dietary supplements containing CLA for the treatment of obesity: evidence from animal and human studies","volume":"44","author":"Larsen","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1124\/pr.59.2.2_REF122","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/ajcn\/76.4.780","article-title":"Effect of a 28-d treatment with L-796568, a novel \u03b23-adrenergic receptor agonist, on energy expenditure and body composition in obese men","volume":"76","author":"Larsen","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/pr.59.2.2_REF123","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/j.1550-8528.1995.tb00160.x","article-title":"Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects","volume":"3","author":"Lawton","year":"1995","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF124","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrd1631","article-title":"The histamine H3 receptor: from gene cloning to H3 receptor drugs","volume":"4","author":"Leurs","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pr.59.2.2_REF125","first-page":"1198","article-title":"Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs","volume":"4","author":"Levens","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/pr.59.2.2_REF126","first-page":"R2222","article-title":"Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats","volume":"279","author":"Levin","year":"2000","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.59.2.2_REF127","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: pharmacologic treatment of obesity","volume":"142","author":"Li","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.59.2.2_REF128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2796.2000.00720.x","article-title":"The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study","volume":"248","author":"Lindgarde","year":"2000","journal-title":"J Intern Med"},{"issue":"Pt 1","key":"10.1124\/pr.59.2.2_REF129","first-page":"E627","article-title":"Melanin-concentrating hormone: a functional melanocortin antagonist in the hypothalamus","volume":"274","author":"Ludwig","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.59.2.2_REF130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-2004-814222","article-title":"Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion","volume":"36","author":"Lugari","year":"2004","journal-title":"Horm Metab Res"},{"key":"10.1124\/pr.59.2.2_REF131","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.ijo.0803074","article-title":"A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion","volume":"30","author":"Lustig","year":"2006","journal-title":"Int J Obes (Lond)"},{"key":"10.1124\/pr.59.2.2_REF132","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1210\/jc.2002-030003","article-title":"Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial","volume":"88","author":"Lustig","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"Pt 1","key":"10.1124\/pr.59.2.2_REF133","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0022-3476(99)70017-X","article-title":"Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist","volume":"135","author":"Lustig","year":"1999","journal-title":"J Pediatr"},{"key":"10.1124\/pr.59.2.2_REF134","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4158\/EP.12.1.18","article-title":"Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents","volume":"12","author":"Maahs","year":"2006","journal-title":"Endocr Pract"},{"key":"10.1124\/pr.59.2.2_REF135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2004.04.041","article-title":"Increased ATP content\/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside","volume":"1020","author":"MacLean","year":"2004","journal-title":"Brain Res"},{"key":"10.1124\/pr.59.2.2_REF136","doi-asserted-by":"crossref","first-page":"6957","DOI":"10.1073\/pnas.92.15.6957","article-title":"Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus","volume":"92","author":"Maffei","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.59.2.2_REF137","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.metabol.2003.06.003","article-title":"Effect of pramlintide on A1c and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis","volume":"52","author":"Maggs","year":"2003","journal-title":"Metabolism"},{"issue":"Suppl 1","key":"10.1124\/pr.59.2.2_REF138","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/sj.ejcn.1602172","article-title":"Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study","volume":"59","author":"Mathus-Vliegen","year":"2005","journal-title":"Eur J Clin Nutr"},{"key":"10.1124\/pr.59.2.2_REF139","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.6729459","article-title":"Blood pressure and nutrient intake in the United States","volume":"224","author":"McCarron","year":"1984","journal-title":"Science (Wash DC)"},{"key":"10.1124\/pr.59.2.2_REF140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","article-title":"Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial","volume":"160","author":"McElroy","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1124\/pr.59.2.2_REF141","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4088\/JCP.v65n0108","article-title":"Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial","volume":"65","author":"McElroy","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/pr.59.2.2_REF142","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.4088\/JCP.v65n1104","article-title":"Topiramate in the long-term treatment of binge-eating disorder associated with obesity","volume":"65","author":"McElroy","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/pr.59.2.2_REF143","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial","volume":"160","author":"McMahon","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1124\/pr.59.2.2_REF144","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/diacare.26.1.125","article-title":"A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin","volume":"26","author":"McNulty","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF145","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/BF01930467","article-title":"Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics","volume":"48","author":"Meier","year":"1992","journal-title":"Experientia (Basel)"},{"key":"10.1124\/pr.59.2.2_REF146","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4088\/JCP.v67n0212","article-title":"A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults","volume":"67","author":"Merideth","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/pr.59.2.2_REF147","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1467-789X.2005.00158.x","article-title":"Effect of chitosan on weight loss in overweight and obese individuals: a systematic review of randomized controlled trials","volume":"6","author":"Mhurchu","year":"2005","journal-title":"Obes Rev"},{"key":"10.1124\/pr.59.2.2_REF148","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF149","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/oby.2001.79","article-title":"Orlistat inhibits dietary cholesterol absorption","volume":"9","author":"Mittendorfer","year":"2001","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF150","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","article-title":"Comparison of continuous and intermittent anorectic therapy in obesity","volume":"1","author":"Munro","year":"1968","journal-title":"Br Med J"},{"key":"10.1124\/pr.59.2.2_REF151","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/sj.ijo.0801636","article-title":"Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients","volume":"25","author":"Nam","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF152","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s002130100724","article-title":"Repeated administration of the D1\/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine","volume":"155","author":"Nann-Vernotica","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1124\/pr.59.2.2_REF153","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.4065\/79.8.1059","article-title":"Exercise-induced syncope associated with QT prolongation and ephedra-free Xenadrine","volume":"79","author":"Nasir","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1124\/pr.59.2.2_REF154","series-title":"The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults","year":"2000"},{"key":"10.1124\/pr.59.2.2_REF154a","first-page":"977","article-title":"Health implications of obesity","volume":"103","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.59.2.2_REF156","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1021\/jm058240i","article-title":"5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents","volume":"49","author":"Nilsson","year":"2006","journal-title":"J Med Chem"},{"key":"10.1124\/pr.59.2.2_REF157","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archinte.164.13.1395","article-title":"Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis","volume":"164","author":"Norris","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1124\/pr.59.2.2_REF158","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1345\/aph.1D473","article-title":"Possible association of acute lateral-wall myocardial infarction and bitter orange supplement","volume":"38","author":"Nykamp","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1124\/pr.59.2.2_REF159","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1079\/BJN2003971","article-title":"Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects","volume":"90","author":"O\u2019Donovan","year":"2003","journal-title":"Br J Nutr"},{"key":"10.1124\/pr.59.2.2_REF160","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.59.2.2_REF161","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2004-1965","article-title":"Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome","volume":"90","author":"Ortega-Gonzalez","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pr.59.2.2_REF162","doi-asserted-by":"crossref","unstructured":"Padwal R, Li SK, and Lau DC (2004) Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev CD004094.","DOI":"10.1002\/14651858.CD004094.pub2"},{"key":"10.1124\/pr.59.2.2_REF163","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2337\/diacare.28.3.736","article-title":"A systematic review of drug therapy to delay or prevent type 2 diabetes","volume":"28","author":"Padwal","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF164","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/er.2005-0009","article-title":"The emerging role of the endocannabinoid system in endocrine regulation and energy balance","volume":"27","author":"Pagotto","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1124\/pr.59.2.2_REF165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-8741(90)90092-8","article-title":"Ayurvedic treatment of obesity: a randomized double-blind, placebo-controlled clinical trial","volume":"29","author":"Paranjpe","year":"1990","journal-title":"J Ethnopharmacol"},{"key":"10.1124\/pr.59.2.2_REF166","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0014-2999(02)01427-9","article-title":"Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status","volume":"440","author":"Parker","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.59.2.2_REF167","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ageing\/6.3.179","article-title":"Betahistine hydrochloride (Serc) in cerebrovascular disease: a placebo-controlled study","volume":"6","author":"Pathy","year":"1977","journal-title":"Age Ageing"},{"key":"10.1124\/pr.59.2.2_REF168","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1381\/0960892041590818","article-title":"The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery","volume":"14","author":"Patriti","year":"2004","journal-title":"Obes Surg"},{"key":"10.1124\/pr.59.2.2_REF169","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pr.59.2.2_REF170","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0031-9384(82)90230-X","article-title":"C-terminal octapeptide of cholecystokinin decreases food intake in obese men","volume":"29","author":"Pi-Sunyer","year":"1982","journal-title":"Physiol Behav"},{"key":"10.1124\/pr.59.2.2_REF171","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2337\/diacare.23.8.1154","article-title":"Bromocriptine: a novel approach to the treatment of type 2 diabetes","volume":"23","author":"Pijl","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF172","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/ajcn\/79.4.529","article-title":"Dietary supplements for body-weight reduction: a systematic review","volume":"79","author":"Pittler","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/pr.59.2.2_REF173","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/sj.ijo.0803008","article-title":"Complementary therapies for reducing body weight: a systematic review","volume":"29","author":"Pittler","year":"2005","journal-title":"Int J Obes (Lond)"},{"key":"10.1124\/pr.59.2.2_REF174","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0960-894X(01)00761-2","article-title":"Dihydropyridine neuropeptide Y Y1 receptor antagonists","volume":"12","author":"Poindexter","year":"2002","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/pr.59.2.2_REF175","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/oby.2001.72","article-title":"Lifestyle treatments in randomized clinical trials of pharmacotherapies for obesity","volume":"9","author":"Poston","year":"2001","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF176","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.euroneuro.2003.10.004","article-title":"The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study","volume":"14","author":"Poyurovsky","year":"2004","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1124\/pr.59.2.2_REF177","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1467-789X.2003.00122.x","article-title":"Psychosocial origins of obesity stigma: toward changing a powerful and pervasive bias","volume":"4","author":"Puhl","year":"2003","journal-title":"Obes Rev"},{"key":"10.1124\/pr.59.2.2_REF177a","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00000441-189308000-00001","article-title":"Cases of myxedema and acromegalia treated with benefit by sheep\u2019s thyroids: recent observations respecting the pathology of the cachexias following disease of the thyroid; clinical relationships of grave\u2019s disease and acromegalia","volume":"106","author":"Putnam","year":"1893","journal-title":"Am J Med Sci"},{"key":"10.1124\/pr.59.2.2_REF179","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabete Med"},{"key":"10.1124\/pr.59.2.2_REF180","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1463-1326.2006.00589.x","article-title":"Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus","volume":"8","author":"Ratner","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pr.59.2.2_REF181","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0002-9149(00)01521-6","article-title":"Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X","volume":"87","author":"Reaven","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1124\/pr.59.2.2_REF182","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2337\/diacare.28.6.1311","article-title":"Two-year outcome of a combination of weight loss therapies for type 2 diabetes","volume":"28","author":"Redmon","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF183","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2337\/diacare.29.02.06.dc05-1267","article-title":"Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1","volume":"29","author":"Riddle","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF184","doi-asserted-by":"crossref","first-page":"1146S","DOI":"10.1093\/ajcn\/79.6.1146S","article-title":"Metabolic effects of conjugated linoleic acid in humans: the Swedish experience","volume":"79","author":"Riserus","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/pr.59.2.2_REF185","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1053\/meta.2000.6251","article-title":"Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats","volume":"49","author":"Rodriquez de Fonseca","year":"2000","journal-title":"Metabolism"},{"key":"10.1124\/pr.59.2.2_REF186","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00427624","article-title":"Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects","volume":"66","author":"Rogers","year":"1979","journal-title":"Psychopharmacology"},{"key":"10.1124\/pr.59.2.2_REF187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.1550-8528.1998.tb00308.x","article-title":"Sibutramine reduces food intake in nondieting women with obesity","volume":"6","author":"Rolls","year":"1998","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF188","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1210\/jcem.87.5.8628","article-title":"Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones","volume":"87","author":"Rosenbaum","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pr.59.2.2_REF189","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0031-9384(98)00321-7","article-title":"Effect of the H1-histamine receptor agonist betahistine on drinking and eating behavior in pygmy goats","volume":"66","author":"Rossi","year":"1999","journal-title":"Physiol Behav"},{"key":"10.1124\/pr.59.2.2_REF190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity: European Orlistat Obesity Study Group","volume":"8","author":"Rossner","year":"2000","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF191","unstructured":"Roth D, Weyer C, Anderson CE, Parkes DG, and Baron AD (2006) Leptin responsivity restored in leptin-resistant diet-induced obese rats: synergistic actions of amylin and leptin for reduction in body weight and fat. Handout from American Diabetes Association 66th Annual Scientific Sessions; 2006 June 9\u201313; Washington, DC."},{"key":"10.1124\/pr.59.2.2_REF192","doi-asserted-by":"crossref","first-page":"10730","DOI":"10.1073\/pnas.162349799","article-title":"Adipose tissue mass can be regulated through the vasculature","volume":"99","author":"Rupnick","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.59.2.2_REF193","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.1997.03540300040031","article-title":"Dietary fiber, glycemic load, and risk of noninsulin-dependent diabetes mellitus in women","volume":"277","author":"Salmeron","year":"1997","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pr.59.2.2_REF194","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1081\/ERC-200027356","article-title":"Comparison of efficacy of sibutramine or orlistat versus their combination in obese women","volume":"30","author":"Sari","year":"2004","journal-title":"Endocr Res"},{"key":"10.1124\/pr.59.2.2_REF195","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","article-title":"Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study","volume":"368","author":"Scheen","year":"2006","journal-title":"Lancet"},{"key":"10.1124\/pr.59.2.2_REF196","first-page":"487","article-title":"Effectiveness of phenylpropanolamine in the management of moderate obesity","volume":"16","author":"Schteingart","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF197","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/j.1550-8528.1998.tb00324.x","article-title":"Effects of sibutramine on resting metabolic rate and weight loss in overweight women","volume":"6","author":"Seagle","year":"1998","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF198","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/j.1552-4604.1977.tb04601.x","article-title":"Rheoencephalographic and other studies of betahistine in humans. IV. Prolonged administration with improvement in arteriosclerotic dementia","volume":"17","author":"Seipel","year":"1977","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.59.2.2_REF199","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4088\/JCP.v61n0508","article-title":"Treatment of binge-eating disorder with topiramate: a clinical case series","volume":"61","author":"Shapira","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/pr.59.2.2_REF200","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1352\/0895-8017(2004)109<301:EOTIAW>2.0.CO;2","article-title":"Effects of topiramate in adults with Prader-Willi syndrome","volume":"109","author":"Shapira","year":"2004","journal-title":"Am J Ment Retard"},{"key":"10.1124\/pr.59.2.2_REF201","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1017\/S1461145702002833","article-title":"Topiramate attenuates self-injurious behavior in Prader-Willi syndrome","volume":"5","author":"Shapira","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/pr.59.2.2_REF202","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1210\/jc.2002-021136","article-title":"Effect of calcium supplementation on weight and fat loss in women","volume":"89","author":"Shapses","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pr.59.2.2_REF203","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1359\/jbmr.2001.16.7.1329","article-title":"Bone turnover and density in obese premenopausal women during moderate weight loss and calcium supplementation","volume":"16","author":"Shapses","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1124\/pr.59.2.2_REF204","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-2999(03)02146-0","article-title":"Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats","volume":"475","author":"Shearman","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.59.2.2_REF205","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.289.12.1537","article-title":"Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis","volume":"289","author":"Shekelle","year":"2003","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pr.59.2.2_REF206","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMoa035622","article-title":"Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery","volume":"351","author":"Sjostrom","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.59.2.2_REF207","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicenter Orlistat Study Group","volume":"352","author":"Sjostrom","year":"1998","journal-title":"Lancet"},{"key":"10.1124\/pr.59.2.2_REF208","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2174\/1568007043336950","article-title":"Gut hormones as peripheral anti obesity targets","volume":"3","author":"Small","year":"2004","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1124\/pr.59.2.2_REF209","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0887-8994(02)00490-3","article-title":"Topiramate effectiveness in Prader-Willi syndrome","volume":"28","author":"Smathers","year":"2003","journal-title":"Pediatr Neurol"},{"key":"10.1124\/pr.59.2.2_REF210","first-page":"505","article-title":"On behalf of the members of the sibutramine clinical study 1047 team. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity","volume":"50","author":"Smith","year":"2001","journal-title":"J Fam Pract"},{"issue":"Suppl 1","key":"10.1124\/pr.59.2.2_REF211","first-page":"A80","article-title":"APD356, an orally-active selective 5HT2c agonist reduces body weight in obese men and women","volume":"55","author":"Smith","year":"2006","journal-title":"Diabetes Metab"},{"key":"10.1124\/pr.59.2.2_REF212","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-142-7-200504050-00011","article-title":"Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians","volume":"142","author":"Snow","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.59.2.2_REF213","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1021\/jm0490890","article-title":"Identification of 2-(4-benzyloxyphenyl)-N-[1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity","volume":"48","author":"Souers","year":"2005","journal-title":"J Med Chem"},{"key":"10.1124\/pr.59.2.2_REF214","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ajcn\/30.5.767","article-title":"Metabolic regulation as a control for lipid disorders. Influence of (-)-hydroxycitrate on experimentally induced obesity in the rodent","volume":"30","author":"Sullivan","year":"1977","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/pr.59.2.2_REF215","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1210\/endo.141.6.7490","article-title":"Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats","volume":"141","author":"Szayna","year":"2000","journal-title":"Endocrinology"},{"key":"10.1124\/pr.59.2.2_REF216","first-page":"701","article-title":"Betahistine inhibits food intake in rats","volume":"53","author":"Szelag","year":"2001","journal-title":"Pol J Pharmacol"},{"key":"10.1124\/pr.59.2.2_REF217","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1210\/jc.2004-0835","article-title":"Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome","volume":"89","author":"Tan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pr.59.2.2_REF218","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0014-2999(02)01795-8","article-title":"Betahistine dihydrochloride interaction with the histaminergic system in the cat: neurochemical and molecular mechanisms","volume":"446","author":"Tighilet","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.59.2.2_REF219","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF220","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1067\/mcp.2002.122527","article-title":"Acute effect of L-796568, a novel \u03b23-adrenergic receptor agonist, on energy expenditure in obese men","volume":"71","author":"van Baak","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.59.2.2_REF221","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"10.1124\/pr.59.2.2_REF222","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.ijo.802227","article-title":"Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults","volume":"27","author":"Velasquez-Mieyer","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF223","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2337\/diacare.28.4.942","article-title":"Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies","volume":"28","author":"Vettor","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1124\/pr.59.2.2_REF224","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archinte.161.2.218","article-title":"Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial","volume":"161","author":"Wadden","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1124\/pr.59.2.2_REF225","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/oby.2000.53","article-title":"Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial","volume":"8","author":"Wadden","year":"2000","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF226","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized trial of lifestyle modification and pharmacotherapy for obesity","volume":"353","author":"Wadden","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.59.2.2_REF227","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/BF02244883","article-title":"m-Chlorophenylpiperazine decreases food intake in a test meal","volume":"116","author":"Walsh","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pr.59.2.2_REF228","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/oby.2005.142","article-title":"Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation","volume":"13","author":"Westerterp-Plantenga","year":"2005","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF229","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","article-title":"A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects","volume":"28","author":"Wilding","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pr.59.2.2_REF230","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1389-9457(03)00060-1","article-title":"Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate","volume":"4","author":"Winkelman","year":"2003","journal-title":"Sleep Med"},{"key":"10.1124\/pr.59.2.2_REF231","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","article-title":"Long-term weight loss with sibutramine: a randomized controlled trial","volume":"286","author":"Wirth","year":"2001","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pr.59.2.2_REF232","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.281.21.1998","article-title":"Long-term intake of dietary fiber and decreased risk of coronary heart disease among women","volume":"281","author":"Wolk","year":"1999","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pr.59.2.2_REF233","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.2337\/diabetes.54.8.2390","article-title":"Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial","volume":"54","author":"Wynne","year":"2005","journal-title":"Diabetes"},{"key":"10.1124\/pr.59.2.2_REF234","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJMra012586","article-title":"Obesity","volume":"346","author":"Yanovski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.59.2.2_REF235","first-page":"403","article-title":"Neuropeptide Y in obese women during treatment with adrenergic modulation drugs","volume":"7","author":"Zahorska-Markiewicz","year":"2001","journal-title":"Med Sci Monit"},{"key":"10.1124\/pr.59.2.2_REF236","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.ijo.0802880","article-title":"Dairy augmentation of total and central fat loss in obese subjects","volume":"29","author":"Zemel","year":"2005","journal-title":"Int J Obes (Lond)"},{"key":"10.1124\/pr.59.2.2_REF237","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/oby.2005.144","article-title":"Effects of calcium and dairy on body composition and weight loss in African-American adults","volume":"13","author":"Zemel","year":"2005","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF238","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1096\/fasebj.14.9.1132","article-title":"Regulation of adiposity by dietary calcium","volume":"14","author":"Zemel","year":"2000","journal-title":"FASEB J"},{"key":"10.1124\/pr.59.2.2_REF239","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/oby.2004.67","article-title":"Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults","volume":"12","author":"Zemel","year":"2004","journal-title":"Obes Res"},{"key":"10.1124\/pr.59.2.2_REF240","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/372425a0","article-title":"Positional cloning of the mouse obese gene and its human homolog","volume":"372","author":"Zhang","year":"1994","journal-title":"Nature (Lond)"},{"key":"10.1124\/pr.59.2.2_REF241","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/00912709922007543","article-title":"Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients","volume":"39","author":"Zhi","year":"1999","journal-title":"J Clin Pharmacol"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724117218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724117218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pr.59.2.2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T21:00:47Z","timestamp":1736024447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724117218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":241,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S0031699724117218"],"URL":"https:\/\/doi.org\/10.1124\/pr.59.2.2","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Treatment of the Overweight Patient","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pr.59.2.2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}